Metabolite and thymocyte development defects in ADA-SCID mice receiving enzyme replacement therapy

Area of Science:

• Biochemistry
• Immunology
• Genetics

Background:

• Adenosine deaminase (ADA) deficiency causes severe combined immunodeficiency (SCID), impacting T cell development.
• Enzyme replacement therapy (ERT) using pegylated bovine ADA (PEG-ADA) is a life-saving treatment for ADA-SCID.
• Suboptimal immune recovery is observed in many patients receiving PEG-ADA therapy.

Purpose of the Study:

• To investigate the efficacy of PEG-ADA treatment on thymus cellularity and thymocyte development in ADA-SCID mice.
• To elucidate the underlying metabolic and immunological abnormalities in the thymus despite PEG-ADA treatment.

Main Methods:

• Treatment of ADA-SCID mice with weekly PEG-ADA.
• Analysis of thymus cellularity and thymocyte populations.
• Assessment of adenosine detoxification and apoptosis in thymocytes.

Main Results:

• Weekly PEG-ADA treatment resulted in reduced thymus cellularity in ADA-SCID mice.
• Effective adenosine detoxification was not restored in the thymus.
• Thymocyte development was arrested at the DN3-to-DN4 stage, leading to dATP-induced apoptosis.

Conclusions:

• Exogenous, once-a-week enzyme replacement therapy does not fully correct intra-thymic metabolic and immunological defects in ADA deficiency.
• Further therapeutic strategies are needed to improve immune reconstitution in ADA-SCID.